Krystexxa (pegloticase) for refractory chronic gout
Customize your policy alerts
Sign up for Bluecross Idaho Policy 5.01.665 alerts
Get alerted when Policy 5.01.665 changes without checking for updates manually.
Monitor payer policy activity
Medical necessity criteria, prior authorization guidance, and coverage stance for Krystexxa (pegloticase) in adults with refractory chronic gout for Bluecross Idaho members.
Updated policy statements with initial and continuing approval durations.
Adopted Blue Cross of Idaho policy as revised, effective 04/01/2026.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.